BIOMAT Database Logo BIOMAT Database Logo

The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation. 1982

P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank

Employing an in vitro bactericidal assay using C4-deficient guinea pig serum (C4D-GPS), we evaluated the ability of the alternative pathway to kill a number of strains of encapsulated and unencapsulated Haemophilus influenzae (HI). Complement activation occurred, but no bactericidal activity was observed against any of the tested HI in nonimmune C4D-GPS without detectable antibody to HI-type b (HIb) capsular polysaccharide (HIb-ps). In the presence of high-titered human anti- (type b) IgG, C4D-GPS killed the encapsulated strains. Restoration of classical pathway activity by the addition of purified C4 to C4D-GPS, which contained antibody to somatic antigens, resulted in killing of some strains of both encapsulated and unencapsulated HI. In nonimmune C4D-GPS the alternative pathway is activated but does not mediate bactericidal activity. The addition of specific high-titered anticapsular IgG results in killing of encapsulated HI by the alternative pathway in guinea pig serum.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007106 Immune Sera Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. Antisera,Immune Serums,Sera, Immune,Serums, Immune
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D001770 Blood Bactericidal Activity The natural bactericidal property of BLOOD due to normally occurring antibacterial substances such as beta lysin, leukin, etc. This activity needs to be distinguished from the bactericidal activity contained in a patient's serum as a result of antimicrobial therapy, which is measured by a SERUM BACTERICIDAL TEST. Activities, Blood Bactericidal,Activity, Blood Bactericidal,Bactericidal Activities, Blood,Bactericidal Activity, Blood,Blood Bactericidal Activities
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003170 Complement Pathway, Alternative Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Alternative Complement Pathway,Properdin Pathway,Alternative Complement Activation Pathway,Complement Activation Pathway, Alternative
D003171 Complement Pathway, Classical Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Classical Complement Pathway,Classical Complement Activation Pathway,Complement Activation Pathway, Classical
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003181 Complement C4 A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B. C4 Complement,C4 Complement Component,Complement 4,Complement C4, Precursor,Complement Component 4,Pro-C4,Pro-complement 4,C4, Complement,Complement Component, C4,Complement, C4,Component 4, Complement,Component, C4 Complement,Pro C4,Pro complement 4
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea

Related Publications

P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank
Activation of the alternative complement pathway by Haemophilus influenzae type B.
April 1977, Infection and immunity,
P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank
Activation of complement by Schistosoma mansoni schistosomula: killing of parasites by the alternative pathway and requirement of IgG for classical pathway activation.
October 1979, Journal of immunology (Baltimore, Md. : 1950),
P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank
Antibody-dependent alternative pathway killing of Haemophilus influenzae type b.
May 1984, Infection and immunity,
P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank
Activation of human complement by liposomes: serum factor requirement for alternative pathway activation.
August 1980, Journal of immunology (Baltimore, Md. : 1950),
P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank
Specific antibodies enhance alternative complement pathway activation by cuprophane.
January 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank
Edwardsiella tarda evades serum killing by preventing complement activation via the alternative pathway.
April 2015, Fish & shellfish immunology,
P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank
Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.
April 1998, Infection and immunity,
P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank
The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.
January 1981, Journal of immunology (Baltimore, Md. : 1950),
P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank
Complement-mediated killing of Opisthorchis viverrini via activation of the alternative pathway.
August 1986, International journal for parasitology,
P I Tarr, and S W Hosea, and E J Brown, and R Schneerson, and A Sutton, and M M Frank
Anticapsular polysaccharide IgG concentrations in Mexican children formerly immunized with Haemophilus influenzae b PRP-T vaccine.
January 2007, Human vaccines,
Copied contents to your clipboard!